SG11201407597XA - Nucleophilic catalysts for oxime linkage - Google Patents
Nucleophilic catalysts for oxime linkageInfo
- Publication number
- SG11201407597XA SG11201407597XA SG11201407597XA SG11201407597XA SG11201407597XA SG 11201407597X A SG11201407597X A SG 11201407597XA SG 11201407597X A SG11201407597X A SG 11201407597XA SG 11201407597X A SG11201407597X A SG 11201407597XA SG 11201407597X A SG11201407597X A SG 11201407597XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- water soluble
- soluble polymer
- carbohydrate moiety
- Prior art date
Links
- 150000002923 oximes Chemical class 0.000 title abstract 3
- 239000012011 nucleophilic catalyst Substances 0.000 title abstract 2
- 229920003169 water-soluble polymer Polymers 0.000 abstract 4
- 125000000837 carbohydrate group Chemical group 0.000 abstract 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 150000007857 hydrazones Chemical class 0.000 abstract 1
- 230000000269 nucleophilic effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Water Supply & Treatment (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647814P | 2012-05-16 | 2012-05-16 | |
| US13/488,043 US8809501B2 (en) | 2009-07-27 | 2012-06-04 | Nucleophilic catalysts for oxime linkage |
| PCT/US2013/041280 WO2013173543A1 (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407597XA true SG11201407597XA (en) | 2014-12-30 |
Family
ID=48579473
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407597XA SG11201407597XA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| SG10201911328QA SG10201911328QA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| SG10201701780RA SG10201701780RA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911328QA SG10201911328QA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| SG10201701780RA SG10201701780RA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Country Status (12)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| KR20240045351A (ko) * | 2016-11-14 | 2024-04-05 | 노파르티스 아게 | 연골 손상 및 관절염 치료 방법 및 조성물 |
| JP7002036B2 (ja) * | 2016-11-17 | 2022-01-20 | パナソニックＩｐマネジメント株式会社 | 膜電極接合体および固体酸化物形燃料電池 |
| US11786586B2 (en) | 2016-12-23 | 2023-10-17 | Aoa Dx | Carbohydrate structures and uses thereof |
| CN108503901B (zh) * | 2018-04-17 | 2020-07-07 | 哈尔滨工业大学 | 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法 |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| US11767526B2 (en) | 2019-01-23 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| MX2023009987A (es) | 2021-02-26 | 2023-09-06 | Regeneron Pharma | Tratamiento de la inflamacion con glucocorticoides e inhibidores de angiopoyetina tipo 7 (angptl7). |
| WO2023171638A1 (ja) | 2022-03-07 | 2023-09-14 | 株式会社カネカ | グルタチオンを含む粒状組成物の製造方法 |
| WO2025133203A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| ES2154650T3 (es) | 1992-10-02 | 2001-04-16 | Genetics Inst | Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador. |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| AU7097094A (en) * | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| WO2001087922A2 (en) | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7026440B2 (en) | 2001-11-07 | 2006-04-11 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| RU2329274C2 (ru) | 2002-09-11 | 2008-07-20 | Фрезениус Каби Дойчланд Гмбх | Способ получения производных гидроксиалкилкрахмала |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| US20080206182A1 (en) * | 2003-08-08 | 2008-08-28 | Fresenius Kabi Deutschland Gmbh | Conjugates of a Polymer and a Protein Linked by an Oxime Group |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| ES2422187T3 (es) | 2003-12-03 | 2013-09-09 | Biogenerix Ag | Factor estimulante de colonias de granulocitos glicopegilados |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2593318T3 (es) | 2004-08-12 | 2016-12-07 | Lipoxen Technologies Limited | Derivados de ácido siálico |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| PT1835938E (pt) | 2004-12-27 | 2013-11-06 | Baxter Int | Conjugados de polímero-factor de von willebrand |
| ES2536450T3 (es) | 2005-06-16 | 2015-05-25 | Nektar Therapeutics | Conjugados que tienen una unión degradable y reactivos poliméricos útiles en la preparación de tales conjugados |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| WO2008025856A2 (en) * | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| WO2008074032A1 (en) | 2006-12-15 | 2008-06-19 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| JP5909755B2 (ja) * | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| US8637640B2 (en) * | 2009-07-27 | 2014-01-28 | Baxter International Inc. | Blood coagulation protein conjugates |
| BR112013001611B1 (pt) * | 2010-07-30 | 2022-05-10 | Takeda Pharmaceutical Company Limited | Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo |
| KR101560541B1 (ko) * | 2012-04-13 | 2015-10-19 | 아우토리브 디벨롭먼트 아베 | 에어백 모듈과 스티어링 휠의 조립체 |
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
-
2013
- 2013-04-12 AU AU2013204754A patent/AU2013204754C1/en active Active
- 2013-05-16 SG SG11201407597XA patent/SG11201407597XA/en unknown
- 2013-05-16 EP EP21214357.2A patent/EP4019049A1/en active Pending
- 2013-05-16 EA EA201492115A patent/EA028186B9/ru not_active IP Right Cessation
- 2013-05-16 WO PCT/US2013/041280 patent/WO2013173543A1/en active Application Filing
- 2013-05-16 CN CN201811295900.8A patent/CN109620963B/zh active Active
- 2013-05-16 SG SG10201911328QA patent/SG10201911328QA/en unknown
- 2013-05-16 NZ NZ738846A patent/NZ738846A/en unknown
- 2013-05-16 JP JP2015512831A patent/JP6195611B2/ja active Active
- 2013-05-16 EP EP13728026.9A patent/EP2849795B1/en active Active
- 2013-05-16 KR KR1020217009701A patent/KR102287040B1/ko active Active
- 2013-05-16 KR KR1020217024432A patent/KR102326360B1/ko active Active
- 2013-05-16 CN CN201380037823.5A patent/CN104487095B/zh active Active
- 2013-05-16 EP EP13724491.9A patent/EP2849794A1/en not_active Withdrawn
- 2013-05-16 EA EA201790935A patent/EA035506B1/ru not_active IP Right Cessation
- 2013-05-16 MX MX2014013919A patent/MX360594B/es active IP Right Grant
- 2013-05-16 KR KR1020147035113A patent/KR102110622B1/ko active Active
- 2013-05-16 NZ NZ724828A patent/NZ724828A/en unknown
- 2013-05-16 BR BR112014028636-1A patent/BR112014028636B1/pt active IP Right Grant
- 2013-05-16 NZ NZ701945A patent/NZ701945A/en unknown
- 2013-05-16 KR KR1020207013096A patent/KR102237306B1/ko active Active
- 2013-05-16 NZ NZ738844A patent/NZ738844A/en unknown
- 2013-05-16 CA CA2873756A patent/CA2873756C/en active Active
- 2013-05-16 SG SG10201701780RA patent/SG10201701780RA/en unknown
- 2013-05-16 WO PCT/US2013/041300 patent/WO2013173557A1/en active Application Filing
-
2017
- 2017-06-01 JP JP2017109323A patent/JP6560712B2/ja active Active
-
2019
- 2019-02-05 JP JP2019018663A patent/JP6711935B2/ja active Active
-
2020
- 2020-04-03 JP JP2020067396A patent/JP7014844B2/ja active Active
-
2021
- 2021-12-29 JP JP2021215385A patent/JP7304402B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407597XA (en) | Nucleophilic catalysts for oxime linkage | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201407561UA (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201408307VA (en) | Needle guard | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201901351UA (en) | A patient interface, system and method | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201408312UA (en) | Method of preparing a composition based on hyaluronic acid | |
| SG11201407812SA (en) | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations |